Danegaptide
Oral small-molecule candidate for diabetic retinopathy
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Danegaptide is Breye Therapeutics' lead orally administered small-molecule drug candidate for early retinal disease, including non-proliferative diabetic retinopathy. The company has reported completion of a Phase 1b trial and plans a randomized Phase 2 clinical proof-of-concept study starting in 2027.
- Website
- breye.com
- Added via
- web
- Ownership
- unclaimed
Where to go
For people
- Homepagebreye.com
For agents
Nothing listed yet.